Give me your shorts, your bashers, your negs; in other words your poor. Your bent over buttocks yearning to be reamed. The wretched refuse of your short position. Send these, the naysayers, to another message board.
I pick the Raiders on behalf of my nephew and against my better judgment. My nephew and myself are Zogenix shareholders and he is also a diehard Raider fan. At least he has made money with his ZGNX stock.
I will go out on a limb for his sake and call it Raiders by 6.
ZIOP and ZGNX are good currently and as you know we both hold them, but as for AEZS it has been outperformed by both those stocks significantly. AEZS certainly looks like it is possibly presenting a buying opportunity but I will have to take a closer look to see how I feel about this.
I have been looking at DVAX this month and bought some shares so take a look at this company if you are looking for another stock. In the meantime I will look at AEZS.
Get lost Spam Boy.
There was a $3.50 Shelf Offering earlier this month after the stock had moved from $1.49 to $5.24 and it is now in recovery at $4.15.
I hold both company stocks and got in low on each. Both had Shelf Offerings during November and that slowed their advancements but they look good now as the prices are recovering.
Anything is possible with a high beta microcap biotechnology company stock, even with no significant news, although a lot of water is under the bridge here with approval, a shelf offering, the stock having been at $6 prior with no huge drug and three of four upgrades and higher price targets. I figure that institutional holders are loading up and then when everyone is aboard the train will leave the station.
I sense that the stock has been run down and held back and that we are real close to having a sizeable jump in the share price.
They can see your order and play games with you to chase it, so place a market order and not a limit order and if you have a large broker pulling from many sources it will be filled immediately at that current price that you wanted.
Twenty Four Seven Wall Street
New Top Stocks to Buy Under $10 with Big Upside
By Lee Jackson
November 18, 2013 8:10 am EST
Zogenix Inc. (NASDAQ: ZGNX) is a top new name to buy at Oppenheimer. The U.S. Food and Drug Administration (FDA) recently approved its top new drug Zohydro. The drug is a timed-release form of hydrocodone, which is one of the most highly prescribed pain medications in the world. The Zogenix drug contains no acetaminophen, which has been proven to cause liver damage. This is a boon to patients suffering from oncology-related pain, as often radiation therapy weakens or damages the liver. The Oppenheimer price target for the stock is set at $5. The consensus price target is also at $5. Zogenix closed on Friday at $2.95.